title: Future Directions in Pain Management: Integrating Anatomically Selective Delivery Techniques With Novel Molecularly Selective Agents.
abstract: Treatment for chronic, locoregional pain ranks among the most prevalent unmet medical needs. The failure of systemic analgesic drugs, such as opioids, is often due to their off-target toxicity, development of tolerance, and abuse potential. Interventional pain procedures provide target specificity but lack pharmacologically selective agents with long-term efficacy. Gene therapy vectors are a new tool for the development of molecularly selective pain therapies, which have already been proved to provide durable analgesia in preclinical models. Taken together, advances in image-guided delivery and gene therapy may lead to a new class of dual selective analgesic treatments integrating the molecular selectivity of analgesic genes with the anatomic selectivity of interventional delivery techniques.
authors.affiliation: Department of Anesthesiology and Oncology, Mayo Clinic, Rochester, MN.
authors.forename: Josef
authors.initials: J
authors.lastname: Pleticha
authors.affiliation: Department of Radiology, Mayo Clinic, Rochester, MN.
authors.forename: Timothy P
authors.initials: TP
authors.lastname: Maus
authors.affiliation: Department of Anesthesiology and Oncology, Mayo Clinic, Rochester, MN.
authors.forename: Andreas S
authors.initials: AS
authors.lastname: Beutler
mesh_terms: D000700:Analgesics / Q000627:therapeutic use*; D000701:Analgesics, Opioid / Q000008:administration & dosage*; D059350:Chronic Pain / Q000188:drug therapy*; D005544:Forecasting; D015316:Genetic Therapy / Q000639:trends*; D006801:Humans; D059408:Pain Management / Q000639:trends*; D014481:United States
chemical_list: D000700:Analgesics; D000701:Analgesics, Opioid